title: [Seven cases of gemcitabine-induced lung injury during treatment for pancreatic or biliary tract cancers].
abstract: Gemcitabine is an anti-cancer drug known to be safe and effective for pancreatic or biliary tract cancers, but lung injury is also known to be a rare side effect that sometimes becomes severe. Here we report seven cases of lung injury during gemcitabine treatment. Drug-induced lung injury was suspected in all cases. The male: female ratio was 5:2, and the average patient age was 71. Four had pancreatic cancers and three had biliary tract cancers. Gemcitabine had been administered an average 5.9 times at a dose of 1,141 mg. Patients showed a diffuse or patchy shadow mainly in the lower lung on computed tomography examination. Grades of adverse events were greater than 3 in all cases. Three patients died of the lung injury. Five cases had pulmonary emphysema, 2 had metastatic lung tumor as underlying pulmonary lesions, and these were assumed to have been important risk factors for drug-induced interstitial lung injury during gemcitabine treatment.
authors.affiliation: Dept. of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Japan.
authors.forename: Takehiko
authors.initials: T
authors.lastname: Tsumura
authors.forename: Hiroo
authors.initials: H
authors.lastname: Matsuo
authors.forename: Takanori
authors.initials: T
authors.lastname: Maruo
authors.forename: Hisato
authors.initials: H
authors.lastname: Kawakami
authors.forename: Kiyoaki
authors.initials: K
authors.lastname: Hatano
authors.forename: Sumio
authors.initials: S
authors.lastname: Saito
authors.forename: Norihiro
authors.initials: N
authors.lastname: Nishijima
authors.forename: Masato
authors.initials: M
authors.lastname: Nakatsuji
authors.forename: Atsuyuki
authors.initials: A
authors.lastname: Ikeda
authors.forename: Hiroki
authors.initials: H
authors.lastname: Nishikawa
authors.forename: Ryuichi
authors.initials: R
authors.lastname: Kita
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Okabe
authors.forename: Toru
authors.initials: T
authors.lastname: Kimura
authors.forename: Ryoichi
authors.initials: R
authors.lastname: Amitani
authors.forename: Yukio
authors.initials: Y
authors.lastname: Osaki
mesh_terms: D000368:Aged; D001661:Biliary Tract Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D055370:Lung Injury / Q000139:chemically induced* / Q000000981:diagnostic imaging; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D014057:Tomography, X-Ray Computed; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D000093542:Gemcitabine